Search

Supplemental material, sj-docx-5-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Supplemental material, sj-docx-2-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Supplemental material, sj-docx-1-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Supplemental material, sj-docx-3-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Supplemental material, sj-docx-4-tam-10.1177_17588359231157641 for The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy by Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor and Javier Gallego in Therapeutic Advances in Medical Oncology

Background There is a lack of knowledge about the career paths and employment situation of young medical oncologists. The aim of our study was to evaluate the current professional standing of these professionals in Spain. Methods The Spanish Society of Medical Oncology + MIR section conducted a national online survey in May 2021 of young medical oncology consultants ( Results A total of 162 responses were eligible for analysis and included participants from 16 autonomous communities; 64% were women, 80% were consultants, and 20% were residents. More than half of the participants performed routine healthcare activity and only 7% research activity. Almost three quarters (73%) were subspecialized in a main area of interest and almost half of these chose this area because it was the only option available after residency. Half of the respondents (51%) considered working abroad and 81% believed the professional standing in Spain was worse than in other countries. After finishing their residency, only 22 were offered a job at their training hospital. Just 16% of participants had a permanent employment contract and 87% were concerned (score of ≥ 5 on a scale of 1–10) about their job stability. In addition, one quarter of the participants in our study showed an interest in increasing their research activity. Conclusions The choice of subspecialty in medical oncology may depend on job opportunities after residency rather than personal interest. The abundance of temporary contracts may have influenced the job stability concerns observed. Future mentoring strategies should engage in building a long-term career path for young medical oncologists.

Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity. Methods: 594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab. Results: The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1–21.0) versus ToGA regimens (7.5, 6.4–8.5), p Conclusion: We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX–trastuzumab in clinical practice and point toward a possible benefit of FOLFOX–trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials.

Supplemental material, sj-docx-3-tam-10.1177_17588359211019672 for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry by Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López, Laura Visa, Mónica Granja, Nieves Martínez Lago, Virginia Arrazubi, Rosario Vidal Tocino, Raquel Hernandez, Gema Aguado, Juana María Cano, Alfonso Martín Carnicero, Monserrat Mangas, Paola Pimentel, Ana Fernández Montes, Ismael Macias Declara, Federico Longo, Avinash Ramchandani, Marta Martín Richard, Alicia Hurtado, Aitor Azkarate, Carolina Hernández Pérez, Raquel Serrano and Javier Gallego in Therapeutic Advances in Medical Oncology

Supplemental material, sj-docx-1-tam-10.1177_17588359211019672 for External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry by Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López, Laura Visa, Mónica Granja, Nieves Martínez Lago, Virginia Arrazubi, Rosario Vidal Tocino, Raquel Hernandez, Gema Aguado, Juana María Cano, Alfonso Martín Carnicero, Monserrat Mangas, Paola Pimentel, Ana Fernández Montes, Ismael Macias Declara, Federico Longo, Avinash Ramchandani, Marta Martín Richard, Alicia Hurtado, Aitor Azkarate, Carolina Hernández Pérez, Raquel Serrano and Javier Gallego in Therapeutic Advances in Medical Oncology